Note: This is not an investment advice but my opinion alone. Please feel free to comment.
Since NITE reached its high, it has lost a lot of steam due to the offering and the perception that AGTC was superior treatment. With the recent AGTC news of its drug not having any effect from the latest trial I do not think this will help the stock (NITE) at all.
Bullish Head & Shoulder Pattern Tells You A lot!! Are the initial insiders, sitting with 5,360,000 shares at $14.00 HAPPY with making 0.23 cents a share after IPO lock up expiration happens on 3/27/2018? My feeling in NO WAY. That is why this price action will take off to around $17.00, before insiders sell their shares for $3.00 profit. Just get on bullish trade ...
800M market cap. 23 employees. UK.
69M in cash. Burning $10M/yr
a gene therapy for the treatment of CHM. We expect to begin Phase 3 clinical development of NSR-REP1 in the first half of 2018. Phase II data due?